The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo-Reference-Cited by-同舟云学术

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

Published:2015-10-27 Issue:42 Volume:6 Page:44289-44305
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Vendetti Frank P.¹,Lau Alan²,Schamus Sandra¹,Conrads Thomas P.³,O’Connor Mark J.²,Bakkenist Christopher J.¹⁴

Affiliation:

1. Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

2. Cancer Bioscience, AstraZeneca, Macclesfield, United Kingdom

3. Women's Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, USA

4. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies;Cancer Treatment Reviews;2024-09

2. Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study;Clinical Cancer Research;2024-07-17

3. Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells;Advanced Science;2024-07-08

4. Case report: Innovative treatment for one metastatic thyroid-like follicular carcinoma of the kidney with ATM and POLE mutations;Frontiers in Oncology;2024-06-12

5. Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma;Clinical Cancer Research;2024-03-20